Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis

Sperber, 2021, Worldwide prevalence and burden of functional gastrointestinal disorders, results of rome foundation global study, Gastroenterol, 160, 99, 10.1053/j.gastro.2020.04.014 Van den Houte, 2019, Prevalence and impact of self-reported irritable bowel symptoms in the general population, United Euro Gastroenterol J, 7, 307, 10.1177/2050640618821804 Vasant, 2021, British society of gastroenterology guidelines on the management of irritable bowel syndrome, Gut, 70, 1214, 10.1136/gutjnl-2021-324598 Altobelli, 2017, Low-FODMAP diet improves irritable bowel syndrome symptoms: a meta-analysis, Nutrients, 9, 1 Sniffen, 2018, Choosing an appropriate probiotic product for your patient: an evidence-based practical guide, PLoS ONE, 13, 10.1371/journal.pone.0209205 McFarland, 2018, Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis, Front Med, 5, 1 Szajewska, 2016, ESPGHAN working group for probiotics prebiotics. probiotics for the prevention of antibiotic-associated diarrhea in children, J Pediatr Gastroenterol Nutr, 62, 495, 10.1097/MPG.0000000000001081 Su, 2020, AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders, Gastroenterology, 159, 697, 10.1053/j.gastro.2020.05.059 Ford, 2018, Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome, Aliment Pharmacol Ther, 48, 1044, 10.1111/apt.15001 Wen, 2020, The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials, Intl J Surg, 79, 111, 10.1016/j.ijsu.2020.04.063 Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372, n71, 10.1136/bmj.n71 McFarland, 2008, Meta-analysis of probiotics for the treatment of irritable bowel disease, World J Gastroenterol, 14, 2650, 10.3748/wjg.14.2650 Hill, 2014, Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic, Nat Rev Gastroenterol Hepatol, 11, 506, 10.1038/nrgastro.2014.66 Higgins, 2011 Palmer, 2016 McGuinness, 2019 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Sudha, 2018, Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study, Benef Microbes, 9, 563, 10.3920/BM2017.0129 Madempudi, 2019, Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults, Sci Rep, 9, 12210, 10.1038/s41598-019-48554-x Urgesi, 2014, A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome, Eur Rev Med Pharmacol Sci, 18, 1344 Rogha, 2014, The efficacy of a synbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial, Gastroenterol Hepatol Bed Bench, 7, 156 Majeed, 2016, Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study, Nutr J, 15, 21, 10.1186/s12937-016-0140-6 O'Mahony, 2005, Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles, Gastroenterol, 128, 541, 10.1053/j.gastro.2004.11.050 Whorwell, 2006, Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome, Am J Gastroenterol, 101, 1581, 10.1111/j.1572-0241.2006.00734.x Guyonnet, 2007, Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial, Aliment Pharmacol Ther, 26, 475, 10.1111/j.1365-2036.2007.03362.x Agrawal, 2009, Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation, Alim Pharmacolo Therap, 29, 104, 10.1111/j.1365-2036.2008.03853.x Kruis, 2012, A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome, Int J Colorectal Dis, 27, 467, 10.1007/s00384-011-1363-9 Faghihi, 2015, Efficacy of probiotic escherichia coli Nissle 1917 in patients with irritable bowel syndrome: a double blind placebo-controlled randomized trial, Acta Med Indones, 47, 201 Nobaek, 2000, Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome, Am J Gastroentero, 95, 1231, 10.1111/j.1572-0241.2000.02015.x Niedzielin, 2001, A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome, Eur J Gastroenterol Hepatol, 13, 1143, 10.1097/00042737-200110000-00004 Simren, 2006, Effects of Lactobacillus plantarum 299v on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS) - a randomized, double-blind controlled trial. Presented at Digestive Disease Week, May 20-25, 2006, Los Angeles California, Gastroenterol, 130, A600 Ducrotté, 2012, Clinical trial: lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome, World J Gastroenterol, 18, 4012, 10.3748/wjg.v18.i30.4012 Stevenson, 2014, Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome, Nutrition, 30, 1151, 10.1016/j.nut.2014.02.010 Bausserman, 2005, The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial, J Pediat, 147, 197, 10.1016/j.jpeds.2005.05.015 Gawrońska, 2007, A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children, Aliment Pharmacol Ther, 25, 177, 10.1111/j.1365-2036.2006.03175.x Francavilla, 2010, A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain, Pediatrics, 126, e1445, 10.1542/peds.2010-0467 Pedersen, 2014, Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome, World J Gastroenterol, 20, 16215, 10.3748/wjg.v20.i43.16215 Kianifar, 2015, Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial, Electron Physician, 7, 1255 Maupas, 1983, Traitement des colopathies fonctionnelles. Essai en double aveugle de I’ULTRA-LEVURE [Treatment of irritable bowel syndrome double blind trial of Saccharomyces boulardii], Med Chir Dig, 12, 77 Bennani, 1990, Essai randomise de Saccharomyces boulardii dans le traitement des colopathies fonctionnelles.[Randomized study of S. boulardii for the treatment of functional gastroenteropathies.] L'Objectif, Médical, 73, 56 Choi, 2011, A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life, J Clin Gastroenterol, 45, 679, 10.1097/MCG.0b013e318204593e Kabir, 2011, Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome, Mymensingh Med J, 20, 397 Abbas, 2014, Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial, Eur J Gastroenterol Hepatol, 26, 630, 10.1097/MEG.0000000000000094 Pineton de Chambrun, 2015, A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome, Dig Liv Dis, 47, 119, 10.1016/j.dld.2014.11.007 Spiller, 2016, Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation, United Eur Gastroenterol J, 4, 353, 10.1177/2050640615602571 Gayathri, 2020, Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome, Interl J Colorect Dis, 35, 139, 10.1007/s00384-019-03462-4 Simrén, 2010, Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-a randomized, double-blind, controlled study, Aliment Pharmacol Ther, 31, 218, 10.1111/j.1365-2036.2009.04183.x Sondergaard, 2011, Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial, Scand J Gastroenterol, 46, 663, 10.3109/00365521.2011.565066 Begtrup, 2013, Long-term treatment with probiotics in primary care patients with irritable bowel syndrome–a randomised, double-blind, placebo controlled trial, Scand J Gastroenterol, 48, 1127, 10.3109/00365521.2013.825314 Kajander, 2005, A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6 month intervention, Aliment Pharmacol Ther, 22, 387, 10.1111/j.1365-2036.2005.02579.x Kajander, 2008, Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota, Aliment Pharmacol Ther, 27, 48, 10.1111/j.1365-2036.2007.03542.x Yoon, 2014, Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial, J Gastroenterol Hepatol, 29, 52, 10.1111/jgh.12322 Yoon, 2015, Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial, J Clin Biochem Nutr, 57, 129, 10.3164/jcbn.15-14 Ki Cha, 2012, The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial, J Clin Gastroenterol, 46, 220, 10.1097/MCG.0b013e31823712b1 Ko, 2013, Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial, Evid Based Complement Alternat Med, 2013, 10.1155/2013/824605 Kim, 2003, A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 17, 895, 10.1046/j.1365-2036.2003.01543.x Kim, 2005, A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating, Neurogastroenterol Motil, 17, 687, 10.1111/j.1365-2982.2005.00695.x Guandalini, 2010, VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study, J Pediatr Gastroenterol Nutr, 51, 24, 10.1097/MPG.0b013e3181ca4d95 Staudacher, 2017, A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: a randomized controlled trial, Gastroenterology, 153, 936, 10.1053/j.gastro.2017.06.010 Liang, 2019, Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis, Medicine, 98, e16068, 10.1097/MD.0000000000016068 Niu, 2020, The efficacy and safety of probiotics in patients with irritable bowel syndrome: evidence based on 35 randomized controlled trials, Intl J Surg, 75, 116, 10.1016/j.ijsu.2020.01.142 Yuan, 2017, Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis, Curr Med Res Opin, 33, 1191, 10.1080/03007995.2017.1292230 Allen, 2017, Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome. Strain specificity, symptoms and mechanisms, Curr Med Res Opin, 33, 1349, 10.1080/03007995.2017.1322571 Cayzeele-Decherf, 2017, Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: an individual subject meta-analysis, World J Gastroenterol, 23, 336, 10.3748/wjg.v23.i2.336 Zorzela, 2017, Is there a role for modified probiotics as beneficial microbes: a systematic review of the literature, Benef Microbes, 8, 739, 10.3920/BM2017.0032 Sugahara, 2017, Differences between live and heat-killed bifidobacteria in the regulation of immune function and the intestinal environment, Benef Microbes, 8, 463, 10.3920/BM2016.0158 Salminen, 2021, The international scientific association of probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics, Nat Rev Gastroenterol Hepatol, 18, 649, 10.1038/s41575-021-00440-6